Private company

Scopus BioPharma Inc.

American pharmaceutical preparations company based in New York1

In its 2023 annual report the company says: “We are a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc., our majority-owned subsidiary.”37

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business address420 Lexington Avenue, Suite 300, New York, Ny 101702
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-$8.1MFree cash flow3

Financial statements

Revenue453$0 in 2022
02019: $0$020192020: $0$020202021: $0$020212022: $0$02022
Operating income453-$11.7M in 2022+336% since 2019
-$30.0M-$20.0M-$10.0M02019: -$2.7M-$2.7M20192020: -$10.2M-$10.2M2020+278%2021: -$27.6M-$27.6M2021+172%2022: -$11.7M-$11.7M2022−58%
Net income453-$11.6M in 2022+332% since 2019
-$30.0M-$20.0M-$10.0M02019: -$2.7M-$2.7M20192020: -$10.9M-$10.9M2020+304%2021: -$27.0M-$27.0M2021+148%2022: -$11.6M-$11.6M2022−57%
Fiscal year20182019202020212022
Revenue$04$05$03$03
Research and development$463.1K4$7.4M5$15.0M3$2.7M3
Operating expenses$27.6M3$11.7M3
Operating income-$2.7M4-$10.2M5-$27.6M3-$11.7M3
Interest$04$706.4K5$774.7K3$03
Net income-$2.7M4-$10.9M5-$27.0M3-$11.6M3
Earnings per share-$0.815-$1.563-$0.553
Earnings per share (diluted)-$0.815-$1.563-$0.553
Shares (weighted, basic)17.3M shares321.1M shares3
Shares (weighted, diluted)17.3M shares321.1M shares3

Compare Scopus BioPharma Inc. with another company

Corporate structure

Scopus BioPharma Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Scopus BioPharma Inc.

  • ARMISTICE CAPITAL, LLC Filed SC 13G on Scopus BioPharma Inc., latest Feb 15, 2022
  • HCFP/Capital Partners 18B-1 LLC Filed SC 13D on Scopus BioPharma Inc., latest Nov 26, 2021
  • HCFP/Capital Partners 18B-2 LLC Filed SC 13D/A on Scopus BioPharma Inc., latest Nov 26, 2021
  • SCPS/Strategic Capital Partners LLC Filed SC 13D/A on Scopus BioPharma Inc., latest Nov 26, 2021
  • Scopus BioPharma Inc. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Scopus BioPharma Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$2.3K3 Dec 31, 2022$2.8K3 Dec 31, 2021−20.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$124.6K3 Dec 31, 2022$7.9M3 Dec 31, 2021−98.4%

Leadership

Who has led Scopus BioPharma Inc., and when. Pick a name to see everywhere that person has worked.

Chair

  1. Joshua R. Lamstein2020–2021
  2. Ira Scott Greenspan2021

President

  1. Ashish P. Sanghrajka2020
2025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDavid A. Buckel named Dec 7, 202119

Timeline

  1. Aug 18, 20238-K Bylaws or fiscal year changed20
  2. Aug 11, 20238-K Shareholder vote21
  3. Dec 16, 20228-K Listing notice or transfer22
  4. Dec 2, 20228-K Listing notice or transfer23
  5. Oct 20, 20228-K Entered a material agreement24
  6. Oct 19, 20228-K Other events25
  7. Oct 7, 20228-K Listing notice or transfer26
  8. Sep 16, 20228-K Listing notice or transfer27
  9. Sep 2, 20228-K Listing notice or transfer28
  10. Jul 15, 20228-K Listing notice or transfer29
  11. May 27, 20228-K Listing notice or transfer30
  12. May 20, 20228-K Executive or director change31

Filings

73 filings to the SEC since October 2021: 4 annual reports, 6 quarterly reports, 25 major events, 4 insider forms, 4 large holders, 1 private raises, 29 other. The latest 20:

  1. Feb 9, 20241-Z EDGAR
  2. Jan 19, 202415-12G EDGAR
  3. Aug 18, 20238-K EDGAR
  4. Aug 11, 202310-Q EDGAR
  5. Aug 11, 20238-K EDGAR
  6. Jul 21, 2023DEF 14A EDGAR
  7. Jun 28, 2023PRER14A EDGAR
  8. May 12, 202310-Q EDGAR
  9. Apr 28, 202310-K/A EDGAR
  10. Apr 14, 202310-K EDGAR
  11. Mar 31, 2023NT 10-K EDGAR
  12. Dec 16, 20228-K EDGAR
  13. Dec 2, 2022PRE 14A EDGAR
  14. Dec 2, 20228-K EDGAR
  15. Nov 21, 202210-Q EDGAR
  16. Nov 15, 2022NT 10-Q EDGAR
  17. Oct 20, 20228-K EDGAR
  18. Oct 19, 20228-K EDGAR
  19. Oct 7, 20228-K EDGAR
  20. Sep 16, 20228-K EDGAR

The 73 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 23, 2021Raised $9.8 million in a private offering of equity Form D: 4 investors so far Form D

SEC filer profile

How Scopus BioPharma Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARScopus BioPharma Inc.1
  • CIK0001772028
  • Employer ID (EIN)82-12480201
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address420 Lexington Avenue, Suite 300, New York, NY 101701
  • Phone(212) 479-25131
  • Shares outstanding42,084,264 as of Aug 11, 20237
  • Public float$1.1M as of Dec 30, 202236
  • On EDGAR sinceApr 3, 20191
  • Filings190 in all: 8-K (31), 4 (21), DEFA14A (12), 3 (11), 10-Q (9), CORRESP (9), UPLOAD (6), D (5)1
    All 53 form types

    DFAN14A (5), 1-A POS (4), 1-A/A (4), 253G1 (4), 253G2 (4), QUALIF (4), S-1/A (4), SC 13D (4), 10-K (3), 10-K/A (3), SC 13D/A (3), SC 13G (3), 1-A (2), 1-U (2), CT ORDER (2), DEFC14A (2), FWP (2), NT 10-K (2), NT 10-Q (2), PREC14A (2), 1-K (1), 1-SA (1), 1-Z (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B2 (1), 8-A12B (1), 8-K/A (1), CERT (1), D/A (1), DEF 14A (1), DOS (1), DOS/A (1), DOSLTR (1), DRS (1), DRS/A (1), EFFECT (1), PRE 14A (1), PRER14A (1), PRRN14A (1), RW (1), S-1 (1), S-3 (1), SC TO-C (1)

  • Latest filingsAnnual report (10-K) Apr 14, 2023
    Quarterly report (10-Q) Aug 11, 2023
    Proxy statement (DEF 14A) Jul 21, 2023
    Latest 8-K (8-K) Aug 18, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37